ES2155566T3 - Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia. - Google Patents

Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia.

Info

Publication number
ES2155566T3
ES2155566T3 ES96119613T ES96119613T ES2155566T3 ES 2155566 T3 ES2155566 T3 ES 2155566T3 ES 96119613 T ES96119613 T ES 96119613T ES 96119613 T ES96119613 T ES 96119613T ES 2155566 T3 ES2155566 T3 ES 2155566T3
Authority
ES
Spain
Prior art keywords
clamidia
treatment
group
infectious diseases
rifamycin derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96119613T
Other languages
English (en)
Inventor
Katsuji Yamashita
Kazunori Hosoe
Takayoshi Hidaka
George Todaro
Ribhi M Shawar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Application granted granted Critical
Publication of ES2155566T3 publication Critical patent/ES2155566T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

TRATAMIENTO DE ENFERMEDADES CAUSADAS POR INFECCION DE CLAMIDIA MEDIANTE UN DERIVADO DE RIFAMICINA DE LA FORMULA (I): SIENDO R{SUP,1} UN ATOMO DE HIDROGENO O UN GRUPO ACETIL, Y X UN ATOMO DE OXIGENO, UN ATOMO DE SULFURO O UN GRUPO NR EN EL QUE R ES UN ATOMO DE HIDROGENO, UN GRUPO ALQUIL QUE TIENE DE 1 A 7 ATOMOS DE CARBONO O UN GRUPO DE LA FORMULA (II): EN LA QUE N ES UN INTEGRO DE 1 A 3; O UN COMPUESTO SALINO DE LA MISMA ACEPTABLE FISIOLOGICAMENTE.
ES96119613T 1995-12-08 1996-12-06 Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia. Expired - Lifetime ES2155566T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32088295 1995-12-08
JP00263496A JP3963976B2 (ja) 1995-12-08 1996-01-10 クラミジア感染症治療剤

Publications (1)

Publication Number Publication Date
ES2155566T3 true ES2155566T3 (es) 2001-05-16

Family

ID=26336071

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96119613T Expired - Lifetime ES2155566T3 (es) 1995-12-08 1996-12-06 Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia.

Country Status (6)

Country Link
US (1) US5786349A (es)
EP (1) EP0778022B1 (es)
JP (1) JP3963976B2 (es)
CA (1) CA2192255C (es)
DE (1) DE69612465T2 (es)
ES (1) ES2155566T3 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006328080A (ja) * 1995-12-08 2006-12-07 Kaneka Corp クラミジア感染症治療剤
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6900204B2 (en) * 2001-09-06 2005-05-31 Activbiotics, Inc. Antimicrobial agents and uses thereof
JP2005510534A (ja) * 2001-11-21 2005-04-21 アクティブバイオティクス インコーポレイティッド 標的化治療薬およびその使用
WO2003051299A2 (en) * 2001-12-13 2003-06-26 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
CA2490062A1 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
TW200418485A (en) * 2002-09-23 2004-10-01 Activbiotics Inc Rifalazil compositions and therapeutic regimens
WO2004054513A2 (en) * 2002-12-12 2004-07-01 Activbiotics, Inc. Methods and compositions for treating and preventing ear infections
US20040176404A1 (en) * 2002-12-12 2004-09-09 Sayada Chalom B. Methods and reagents for treating or preventing atherosclerosis and diseases associated therewith
WO2005020894A2 (en) * 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
CA2538078C (en) * 2003-09-25 2012-12-04 Activbiotics, Inc. Rifalazil formulations
WO2005058231A2 (en) * 2003-12-10 2005-06-30 Activbiotics, Inc. Rifamycin analogs and uses thereof
CA2550729A1 (en) * 2003-12-23 2005-07-14 Activbiotics, Inc. Rifamycin analogs and uses thereof
US20070248668A1 (en) * 2006-04-06 2007-10-25 Michaelis Arthur F Pharmaceutical compositions and uses thereof
WO2007148714A1 (ja) * 2006-06-21 2007-12-27 Kaneka Corporation リファマイシン誘導体を用いたインプラント
WO2007148713A1 (ja) * 2006-06-21 2007-12-27 Kaneka Corporation リファマイシン誘導体を有効成分とする血管性疾患処置剤または細胞増殖調節剤
SI3004162T1 (sl) 2013-05-31 2020-07-31 Genentech, Inc. Protitelesa in konjugati, ki so usmerjeni proti celični steni bakterij, v kateri je teihoična kislina
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
CA2913011A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
US20170196917A1 (en) 2014-05-15 2017-07-13 Kabushiki Kaisha Yakult Honsha Agent for prevention and treatment of chlamydia infection
RU2731055C2 (ru) 2014-12-03 2020-08-28 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
CA2966211A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690919A (en) * 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS61128621A (ja) 1984-11-27 1986-06-16 Rohm Co Ltd フリツプフロツプ回路
JPS63183587A (ja) 1985-02-05 1988-07-28 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノリフアマイシン誘導体
CA1304363C (en) * 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JP2544488B2 (ja) * 1988-11-01 1996-10-16 鐘淵化学工業株式会社 ３’―ヒドロキシベンゾキサジノリファマイシン誘導体
JP2862912B2 (ja) * 1989-09-14 1999-03-03 鐘淵化学工業株式会社 ５’―（４―プロピルまたは４―イソプロピルピペラジニル）ベンゾキサジノリファマイシン誘導体

Also Published As

Publication number Publication date
DE69612465D1 (de) 2001-05-17
EP0778022B1 (en) 2001-04-11
JP3963976B2 (ja) 2007-08-22
CA2192255A1 (en) 1997-06-09
DE69612465T2 (de) 2001-08-23
EP0778022A1 (en) 1997-06-11
CA2192255C (en) 2004-07-13
US5786349A (en) 1998-07-28
JPH09216824A (ja) 1997-08-19

Similar Documents

Publication Publication Date Title
ES2155566T3 (es) Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia.
CO4410321A1 (es) Compuestos ciclicos condensados con funciones aminoacidas sustituidas y derivados ester de los mismos
ES2190469T3 (es) Derivados de isocumarina y su uso en farmacos.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2174989T3 (es) Pirido(3,2-e)pirazinonas con antiasmatica y procedimiento para su preparacion.
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
HUP0000343A2 (hu) 1,3-Propándiol-származékok alkalmazása szervátültetés után fellépő kilökődés megakadályozására
ES2095772T3 (es) Utilizacion de derivados de rifamicina para producir un medicamento destinado al tratamiento de la toxoplasmosis.
NZ334848A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases caused by fungi and bacteria
ES2182114T3 (es) Derivados azabiciclicos de la carbamoiloxi-multilina para empleo antibacteriano.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
DE3869075D1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE69423339D1 (de) Epoxycyclohexendionderivat
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
KR960003719A (ko) 녹내장 치료제 및 안압 강하제
PT89082A (pt) Processo para a preparacao de novos derivados n-(23-vinblastinoilicos)do acido 1-amino-metilfosfonico
KR960703843A (ko) 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient)
DE69533298D1 (de) Dioxabicyclo 3.3.0 octan-Derivate, z.B. Sesamin etc., zur Vorbeugung und Erleichterung von Allergiesymptomen
ATE184282T1 (de) Cyclopropan-derivate und diese enthaltende antivirale mittel
DE69519895D1 (de) Pyrimidinderivate und pharmazeutische Zusammensetzungen
KR920702685A (ko) 4,6-o- 히드록시포스포릴글루코사민 유도체
AR034088A1 (es) Composicion que comprende derivados anticonvulsivantes utiles en el tratamiento de esquizofrenia y el uso de dicho derivado para la manufactura de un medicamento
ES2096800T3 (es) Benzo(b)tiofen-3-il-piperazinas, un procedimiento para su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 778022

Country of ref document: ES